Analystreport

Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at Mizuho from $25.00 to $28.00. They now have a "buy" rating on the stock.

Coherus BioSciences, Inc.  (CHRS) 
Last coherus biosciences, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.coherus.com